When was Scailyte founded?

Scailyte was founded in 2017 and raised its 1st funding round within a year of its incorporation.

Where is Scailyte located?

Scailyte is headquartered in Basel, Switzerland.

How many employees does Scailyte have?

As of Oct 31, 2026, the latest employee count at Scailyte is 17.

Is Scailyte a funded company?

Scailyte is a funded company, having raised a total of $20.3M across 8 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Jul 30, 2017.

When was the latest funding round of Scailyte?

Scailyte's latest funding was a $***** Series A round on Dec 05, 2023, with participation from 0 investor.

Where does Scailyte rank among its competitors?

Scailyte ranks 16th amongst 96 active competitors, of which 30 are funded. It stands 6th in terms of total funding among its competitors. The most recent competitor to raise funding was Lexicon Pharmaceuticals, which secured $55.7M in Feb, 2026.

Who are the top competitors of Scailyte?

Scailyte's top competitors include Seer, Tango Therapeutics and Maze Therapeutics. Among them, Lexicon Pharmaceuticals secured the most recent funding round in February, 2026.

Scailyte - 2026 Company Profile, Team, Funding & Competitors

Company Details

Artificial intelligence (AI) based single-cell data analysis for novel biomarker discovery. The company is developing AI software for single-cell data analysis to discover novel biomarkers for the early and precise detection of a wide range of complex diseases. This AI-based single-cell technology can also be used for the identification of relevant single-cell patterns from mass cytometry data.

Website: www.scailyte.com/
Social

Key Metrics

Founded Year

2017

Location

Basel, Switzerland

Stage

Series A

Total Funding

$20.3M in 8 rounds

Latest Funding Round

Series A, Dec 05, 2023, $*****

Investors

Swisscom & 8 more

Ranked

16^th among 96 active competitors

Employee Count

17 as on Oct 31, 2026

Similar Companies

OpenEvidence & 2964 more

View Scailyte's full profile

Scailyte has raised a total funding of $20.3M over 8 rounds. Its first funding round was on Jul 30, 2017. Scailyte has 9 institutional investors.

Here is the list of recent funding rounds of Scailyte:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Dec 05, 2023	5896880	Series A	7896705	4739122	6770071	7614387
Sep 21, 2022	1057162	Series A	3599743	3021489	7377364	Swisscom
Jan 10, 2022	9003326	Series A	4088679	5778786	5415072	7384476

Access funding benchmarks and valuations. Sign up today!

View details of Scailyte's funding rounds and investors

The founders of Scailyte are Daniel Sonnleithner, Manfred Claassen and Dennis Göhlsdorf.

Here are the details of Scailyte's key team members:

Daniel Sonnleithner: Co-Founder & COO of Scailyte.
Contact Info: 1 email address
Manfred Claassen: Co-Founder of Scailyte.
Contact Info: 1 email address
Dennis Göhlsdorf: Co-Founder & CTO of Scailyte.
Contact Info: 1 email address

View details of Scailyte's Founder profiles and Board Members

Scailyte's employee count trend

Scailyte has 17 employees as of Oct 26. Here is Scailyte's employee count trend over the years:

Uncover Scailyte's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Scailyte include Seer, Tango Therapeutics and Maze Therapeutics. Here is the list of Top 10 competitors of Scailyte, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Seer 2017, San Francisco (United States), Public	Developer of proteomics platform for early detection of cancer and neurological diseases	$128M	aMoon, Fidelity Investments & 15 others	72/100
2nd	Tango Therapeutics 2017, Cambridge (United States), Public	Developer of drugs for the treatment of cancer	$165M	Boxer Capital, Casdin Capital & 8 others	71/100
3rd	Maze Therapeutics 2018, Redwood City (United States), Public	Developer of genetic bio-markers in neurological, metabolic, and renal diseases	$496M	Matrix Capital Management, Frazier Life Sciences ... & 21 others	66/100
4th	Metabolon 2000, Morrisville (United States), Series H	Provider of solutions for biomarker discovery, diagnostic tests and personalized medicine	$166M	Sevin Rosen, Syngenta Group Ventures & 17 others	66/100
5th	Lexicon Pharmaceuticals 1995, The Woodlands (United States), Public	Developer of small molecule drugs for diffrent health diseases	-	Bay City Capital, New Enterprise Associates ... & 3 others	64/100
6th	Wobble Genomics 2020, Edinburgh (United Kingdom), Series A	Provider of a platform for discovery of nucleic acid biomarkers	$12.5M	Mercia, Eos Advisory & 35 others	62/100
7th	Oxford Biodynamics 2007, Oxford (United Kingdom), Public	Developer of personalized diagnostics by identifying biomarkers through epigenetics	$11M	Armistice Capital, Oxford University Innovation ... & 1 others	56/100
8th	Proteomics International 2001, Perth (Australia), Public	Medical technology company at the forefront of predictive diagnostics and bio-analytical services	-	MTPConnect, NorthStar Impact	55/100
9th	Denovo Biopharma 2013, San Diego (United States), Series D	Developer of genomic biomarker discovery platform	$172M	Guangzhou Yuexiu Industrial Investment Fund Management, CICC ... & 12 others	55/100
10th	Valirx 2000, London (United Kingdom), Public	Developer of novel technologies and products in oncology therapeutics and diagnostics	-	-	53/100
16th	Scailyte 2017, Basel (Switzerland), Series A	Artificial intelligence (AI) based single-cell data analysis for novel biomarker discovery	$20.3M	Verve Ventures, Zurcher Kantonalbank & 7 others	45/100